C. diff Risk


Oral Bioavailability


Approximate Cost



600 mg IV q12h

MRSA bloodstream infections/endocarditis may require higher dosing and should only be undertaken with Infectious Diseases or Antimicrobial Stewardship Program input.

Infectious Diseases consultation required for use, per policy HS1444

General Information

Acceptable Uses

  • Complicated skin/skin structure infections*

  • Community-acquired bacterial pneumonia*

  • Salvage for sustained MRSA bacteremia/endocarditis*

  • Must meet the following criteria for use:

  • MRSA is highly suspected or documented AND vancomycin is not an option

  • MRSA with a vancomycin MIC ≥ 2

  • Sustained difficulty in achieving appropriate vancomycin levels despite clinical pharmacy assistance with pharmacokinetics or where a vancomycin continuous infusion is not an option.

  • Treatment of mixed infections, requires documentation of susceptibility

Unacceptable Uses

  • Selected over vancomycin in patients with renal failure solely as a reason to avoid vancomycin

  • Selected solely for convenience

Common Usage

Ceftaroline is FDA-approved for treatment of skin/skin structure infections (including cases caused by MRSA) and community-acquired pneumonia (including cases caused by penicillinresistant S. pneumoniae).

While there are animal models and case reports of successful use of ceftaroline for the treatment of osteomyelitis, bacteremia, and endocarditis, ceftaroline is not yet FDA-approved for these indications.

Drug Monitoring


  • Cr weekly


  • Hypersensitivity

  • Diarrhea,

  • Other GI effects

Adverse Effects

  • GI effects

  • Hypersensitivity reactions

  • C. difficile

  • Generally well-tolerated